American Century Companies
TGTX icon

American Century Companies’s TG Therapeutics TGTX Stock Holding History

American Century Companies’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,209
Closed -$239K – 2953
2024
Q3 		$239K Buy
+10,209
New +$223K ﹤0.01% 2720

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

American Century Companies's TGTX Position: Q4 2024 in Review

American Century Companies sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 10,209 shares — an estimated $239K sold.

American Century Companies first reported a position in TGTX in Q3 2024 and held it in 1 quarter. The position peaked at $239K in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • American Century Companies reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • American Century Companies sold 10,209 TG Therapeutics shares in Q4 2024, an estimated $239K.
  • American Century Companies first reported a position in TG Therapeutics in Q3 2024 and held it in 1 quarter.
  • American Century Companies's TG Therapeutics position peaked at $239K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on American Century Companies's 13F filing for Q4 2024, filed 11 Feb 2025.